DBTech45 Newsletter Desk

A-Portfolio

One stock a day that deserves a deeper look. Research, never a buy signal.

SPY763
-1.11% today
QQQ710
-2.50% today
IWM270
-1.69% today

A-Portfolio: LYNX, the defense roll-up with a real order book

The company in one breath

Lyntris Inc., ticker LYNX on the New York Stock Exchange, sells sensors, radar electronics, communications gear, and software that help American and allied militaries spot a threat and act on it. The company works on more than 200 defense programs, which means it is spread across many contracts instead of riding one giant bet. Good would look like that broad program base producing repeat orders without one cancellation wrecking the year.

This is not a garage startup. Trive Capital (private) combined two defense businesses, Accelint and Vitesse, after completing 12 acquisitions since 2018. That means Lyntris is a stitched-together platform with useful pieces and integration work still ahead. Good would look like the pieces selling together, margins rising, and the accounting systems finally behaving like one company.

Why now

The stock closed at $15.71 on August 21, according to the Alpaca broker feed. That is 10.2% below the $17.50 IPO price, which means the launch buyers are already underwater. Good entry quality would look like the discount widening while the business evidence stays intact, or the business improving enough to justify paying more.

The deal was cut before launch. Lyntris once aimed for a $19 to $22 range and 24 million shares, then priced 17 million shares at $17.50. That means bankers accepted less money and fewer shares to get the deal done. Good would look like steady trading after the cut, because a weak deal that keeps sliding is not cheap, it is still looking for a floor.

There is a business inflection under the ugly tape. First-half revenue reached $241.0 million, up 34.6%, which means sales grew by roughly one-third from the same period last year. Good for a defense supplier would look like growth staying above the mid-teens while margins recover as newer programs move from design into production.

The numbers, translated

  • Backlog was $923.9 million at June 30, up from $436.1 million a year earlier. Backlog is work the company expects from awarded contracts, not cash in the bank. Good would look like backlog turning into reported revenue while new awards replace the work being delivered.
  • Gross margin was 26.6%, down from 29.2%. Gross margin is the share of each sales dollar left after the direct cost of building the product. Good for this business would look like a return toward 30% as young programs mature, not another slide caused by cost overruns.
  • Operating income was $1.0 million, down from $7.4 million. Operating income is what remained after product costs and normal corporate expenses, before interest and taxes. Good would look like operating profit growing faster than revenue instead of nearly disappearing during a growth surge.
  • Net loss was $13.0 million. The company lost money after paying interest, and its $16.9 million interest bill was larger than operating profit. Good would look like the refinancing cutting interest enough for operating gains to reach common shareholders.
  • Operating cash flow was $34.9 million, versus a $13.3 million cash drain a year earlier. Operating cash flow tracks cash generated by the business, but this improvement leaned heavily on customer prepayments and bills not yet paid. Good would look like positive cash flow continuing without another big working-capital boost.
  • Estimated first-half free cash flow was $29.2 million after $5.7 million of equipment spending. Free cash flow is operating cash left after basic capital spending. Good would look like repeated positive periods, because one burst helped by payment timing is a clue, not proof.
  • The simplified enterprise value is about $2.01 billion, or 4.5 times trailing sales and 26.8 times trailing adjusted EBITDA. Enterprise value adds debt and subtracts cash to estimate the price of the operating business, while adjusted EBITDA is management's preferred profit measure before interest, taxes, depreciation, and selected charges. Good for a leveraged defense supplier would look closer to the high teens on dependable adjusted EBITDA, unless growth and margin expansion stay exceptional.

What I like

The mission mix is right. Maritime surveillance grew 66.0% in the first half, and space intelligence plus resilient communications grew 42.1%. That means two of the three major lines are riding budgets militaries do not treat like optional office furniture. Good would look like air and missile defense, the flat third line, joining the growth.

Customer concentration is better than I expected. No single program supplied more than 7% of 2025 revenue. That means one program delay should hurt, not decapitate the company. Good would look like that ceiling staying below 10% while total program count expands.

The leadership has scar tissue. Chief Executive Brian Morrison previously ran Accelint and held senior roles at AeroVironment (AVAV), General Dynamics (GD), and the U.S. government. That means he knows defense procurement from several sides of the table. Good would look like clean execution across a newly combined public company, not another acquisition spree before the current machine is integrated.

What worries me

This IPO sent more cash to old owners than to the company. Lyntris sold 5.7 million new shares, while existing holders sold 11.3 million shares. That means roughly two-thirds of the deal came from sellers cashing out, not capital funding growth. Good would look like insiders holding the remaining stake and the company using its smaller proceeds to reduce debt exactly as promised.

Debt still owns too much of the story. After refinancing and the planned IPO repayment, I estimate roughly $213 million of borrowings, before lease obligations. That means interest can swallow operating progress, as it already did in the first half. Good would look like net leverage falling every quarter without acquisitions refilling the hole.

The books need adult supervision. Lyntris disclosed unremediated material weaknesses involving financial-close controls, journal entries, information systems, and related-party reviews. A material weakness means the process might fail to prevent or catch a serious accounting error on time. Good would look like a dated remediation plan, successful testing, and no restatement.

The backlog is large, but government backlog can be delayed, reduced, or canceled. It equals about 2.0 times trailing revenue, which means the order book offers visibility but not certainty. Good would look like backlog conversion matching management's schedule and gross margin improving during the conversion.

What would make this a buy

I want one public quarter with revenue growth above 20%, gross margin back above 28%, and positive operating cash flow that does not depend mainly on customer advances. That combination would mean growth, pricing, and cash quality are moving together. Good would look like all three arriving in the same filing, not one metric doing all the work.

I also want the stock below $14 or the profit base materially higher. Below $14, the equity value would fall enough to improve the odds without demanding a broken thesis. Good would look like a cheaper price caused by IPO indigestion, not a lost contract, control failure, or margin blowup.

Finally, management must show debt reduction and control remediation. Good would look like net debt falling, interest expense dropping, and the material weaknesses moving from promises to tested fixes. Until then, the business is interesting and the transaction is mediocre.

What makes me walk away

  • Gross margin stays below 26% for two consecutive quarters. That would mean new-program costs are not maturing as advertised. Good is a rebound, not a permanent reset lower.
  • Backlog falls below $750 million before annual revenue clears $500 million. That would mean the order cushion is eroding faster than sales can replace it. Good is backlog holding near two years of revenue while conversion accelerates.
  • Net debt rises after the IPO repayment. That would mean the balance sheet is getting worse despite fresh equity capital. Good is debt shrinking without another shareholder-funded rescue.
  • A material weakness causes a late filing, restatement, or auditor dispute. That would turn an accounting risk into an accounting event. Good is boring, timely reporting.
  • Management announces another large acquisition before proving this integration works. That would be buying more puzzle pieces before finishing the picture. Good is organic execution first.

Earnings On Deck

  • QumulusAI (QMLS), August 25 after the close. Watch whether signed AI-compute subscriptions become reported revenue and whether deployed power capacity rises without ugly financing. A good print shows accelerating cloud revenue and funded expansion, while a bad print gives us promotional bookings, thin cash, and more dilution.
  • Standard Nuclear (STDN), August 26 after the close. Watch facility authorization, funded-backlog conversion, gross margin, and post-IPO cash. A good print shows new production lines nearing operation and losses improving, while a bad print shows delays, negative unit economics, and cash disappearing faster than fuel ships.

The verdict

Score: 76 out of 100, watch. The company earned points for mission relevance, 34.6% first-half growth, a $923.9 million backlog, customer diversification, and positive first-half cash generation. It lost points for shrinking gross margin, thin operating profit, heavy interest, sponsor selling, unfinished controls, and a valuation that is fair rather than cheap. Candidate status begins at 80. Lyntris is close enough to track and not close enough to force.

The DBTech read

Gross margin tells you what is left after the direct cost of making the product. Lyntris kept 26.6 cents from each sales dollar, before paying office staff, interest, and taxes. A falling margin during fast growth can mean the company is spending heavily to start new programs, which is management's explanation here. Good means those programs mature and the margin climbs because the early engineering pain does not repeat forever. If sales sprint while gross margin crawls backward, the company may be buying growth with its own profit.

Sources and as-of date

As of August 24, 2026. The $15.71 price is the August 21, 2026 official close from the Alpaca SIP broker feed, timestamped at 4:00 p.m. Eastern. The overnight market showed a wide spread and no useful fresh trade, so I used the last completed regular session.

Valuation math uses 115.95 million post-offering shares, the $15.71 close, roughly $213.2 million of estimated post-repayment borrowings, and about $23.7 million of estimated cash after the refinancing and offering. Those last two figures are estimates, not a filed post-IPO balance sheet. Trailing sales equal 2025 revenue plus first-half 2026 revenue minus first-half 2025 revenue. Trailing adjusted EBITDA uses the same bridge.

The Vault
Every issue banked the day it runs. Open any drawer.
Beta 562026-10-16IAM, the AI drug hunter finally has to show its workBeta 552026-10-15HIMS, growth got expensiveBeta 542026-10-14RTSN, an old blood-pressure drug gets one clean shotBeta 532026-10-13HYPR, the MRI that rolls to the patientBeta 522026-10-12TRXB, the science is interesting, the patient proof is not hereBeta 512026-10-09BYRN, the comeback has a pulse, not proofBeta 502026-10-08A Portfolio: Hawaii's deposit machine finally has a tickerBeta 492026-10-07APLD, the AI landlord with a skyscraper-sized bar tabBeta 482026-10-06NAVN, the travel comeback still carries expensive baggageBeta 472026-10-05PENG, the AI boom found its memory problemBeta 462026-10-02ACCV, the AI boom needs electricians tooBeta 452026-10-01RDDT, the internet's opinion factory learned to print moneyBeta 442026-09-30CAVA, the restaurant rocket finally came back to earthBeta 432026-09-29ADRX, serious science at a happy-hour priceBeta 422026-09-28ETRA, a promising drug wrapped in a tiny data setBeta 412026-09-25OIG, fast growth with a storm cloud attachedBeta 402026-09-17SAIL, the AI security story with a private-equity shadowBeta 392026-09-16FBDT, the license is real and the business is not readyBeta 382026-09-15HNGE, a great health business at a swollen priceBeta 372026-09-14NTSK, fast growth with a stock-pay hangoverBeta 362026-09-11ADBE, the cash machine Wall Street refuses to trustBeta 352026-09-10TRBG, the power machine has no sales yetBeta 342026-09-09XTND, the drone story is real and the price is drunkBeta 332026-09-08PSQL, brilliant physics wrapped in brutal financingBeta 322026-09-07CRCL, the stablecoin tollbooth wants to own the roadBeta 312026-09-04ZS, the quarter was better than the stockBeta 302026-09-03CRWV, the AI landlord with a rocket and a mortgageBeta 292026-09-02ADBT, the payday platform with a billion-dollar bar tabBeta 282026-09-01NU, the digital bank earning a grown-up valuationBeta 272026-08-31PATH, the old robot shop wants to run the AI factoryBeta 262026-08-28RBRK, the business is flying and the stock knows itBeta 252026-08-27OKTA, the comeback has a priceBeta 242026-08-26TH, the bunkhouse just found an AI customerBeta 232026-08-25CTRN, the turnaround is real and the stock knows itBeta 222026-08-24LYNX, the defense roll-up with a real order bookBeta 212026-08-21SPCX, the greatest machine with the wildest price tagBeta 202026-08-18KLAR, the checkout button trying to become a bankBeta 192026-08-17FN, the factory behind the AI data-center arms raceBeta 182026-08-14FIG, the design king below its IPO priceBeta 172026-08-13AMBQ, the tiny chip with a giant battery advantage